Genotypic Changes of HBV One Year after Adefovir Dipivoxil Antiviral Treatment

WEN Zhi-li,ZHANG Hai-ming,TAN De-ming,ZHANG Hua,WU Ping,DENG Le
DOI: https://doi.org/10.3969/j.issn.1005-7021.2012.03.010
2012-01-01
Abstract:HBV genotypic changes in vivo of chronic hepatitis B patients one year after adefovir dipivoxil(AD) treatment were observed.152 cases of chronic hepatitis B patients were randomly chosen.52 among them was taken as antiviral treatment group,treated with AD orally,and another 100 was taken as control group,treated with liver protecting tablet(huganpian in Chinese pinyin),both groups were treated for one year period,and respectively visited the patients 3rd,6th,12th month after the treatment,the visiting content including the obedience and harmful reaction of the patients,HbeAG/HbeAb,liver function,HBV,DNA quantitative test and determination.Nested PCR with multiple pairs of genotype-specific primers was used to test and determine dynamically the changes of the HBV genotypes during the treatment.The results showed that one year after the treatment,the HBV genotype in vivo of one patient in antiviral treatment group had changed,changed from genotype B to a mixed genotype of B/C and the patient's condition rebounded and worsened.While in control group,no changes was found in patients' HBV genotype.There was no significant differences(P>0.05) between changing rate of HBV genotypes in two groups(1.9% and 0%).Therefore,HBV genotype in vivo in chronic HB patient could change,and it could easily happen within one year.Antiviral treatment probably was the relative factor of the enhancement of the changes of HBV genotype.The swift of HBV genotype could result in the relapse and worsening of the patient's condition.
What problem does this paper attempt to address?